Reyon Pharmaceutical Co Ltd (102460) - Total Assets
Based on the latest financial reports, Reyon Pharmaceutical Co Ltd (102460) holds total assets worth ₩473.11 Billion KRW (≈ $320.62 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 102460 book value for net asset value and shareholders' equity analysis.
Reyon Pharmaceutical Co Ltd - Total Assets Trend (2008–2024)
This chart illustrates how Reyon Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data.
Reyon Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Reyon Pharmaceutical Co Ltd's total assets of ₩473.11 Billion consist of 17.9% current assets and 82.1% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 2.0% |
| Accounts Receivable | ₩36.72 Billion | 7.3% |
| Inventory | ₩41.99 Billion | 8.4% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩4.60 Billion | 0.9% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Reyon Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 102460 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Reyon Pharmaceutical Co Ltd's current assets represent 17.9% of total assets in 2024, a decrease from 75.6% in 2008.
- Cash Position: Cash and equivalents constituted 2.0% of total assets in 2024, down from 3.2% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2008.
- Asset Diversification: The largest asset category is inventory at 8.4% of total assets.
Reyon Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Reyon Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Reyon Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.60 | 0.63 | 2.42 |
| Quick Ratio | 0.34 | 0.34 | 1.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩-53.78 Billion | ₩-48.77 Billion | ₩69.02 Billion |
Reyon Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Reyon Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.91 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 0.0% |
| Total Assets | ₩499.99 Billion |
| Market Capitalization | $134.11 Million USD |
Valuation Analysis
Below Book Valuation: The market values Reyon Pharmaceutical Co Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Reyon Pharmaceutical Co Ltd's assets decreased by 0.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Reyon Pharmaceutical Co Ltd (2008–2024)
The table below shows the annual total assets of Reyon Pharmaceutical Co Ltd from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩499.99 Billion ≈ $338.84 Million |
+0.04% |
| 2023-12-31 | ₩499.78 Billion ≈ $338.69 Million |
+3.11% |
| 2022-12-31 | ₩484.69 Billion ≈ $328.47 Million |
+1.40% |
| 2021-12-31 | ₩477.98 Billion ≈ $323.92 Million |
+50.49% |
| 2020-12-31 | ₩317.61 Billion ≈ $215.24 Million |
+15.71% |
| 2019-12-31 | ₩274.48 Billion ≈ $186.01 Million |
-9.46% |
| 2018-12-31 | ₩303.17 Billion ≈ $205.45 Million |
+4.24% |
| 2017-12-31 | ₩290.84 Billion ≈ $197.10 Million |
+38.80% |
| 2016-12-31 | ₩209.54 Billion ≈ $142.00 Million |
+33.53% |
| 2012-12-31 | ₩156.92 Billion ≈ $106.34 Million |
+16.93% |
| 2011-12-31 | ₩134.20 Billion ≈ $90.95 Million |
+63.83% |
| 2009-12-31 | ₩81.91 Billion ≈ $55.51 Million |
+25.50% |
| 2008-12-31 | ₩65.27 Billion ≈ $44.23 Million |
-- |
About Reyon Pharmaceutical Co Ltd
REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough … Read more